查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446434

癌症支持治療藥物市場：按類型、應用、分銷管道分類：2023-2032年全球機會分析和產業預測

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 338 Pages | 商品交期: 2-3個工作天內

價格
癌症支持治療藥物市場-IMG1

癌症支持治療藥物的主要促進因素是癌症盛行率的增加以及與抗癌藥物使用相關的副作用，例如化療引起的貧血、噁心和嘔吐。

例如，2022 年 2 月，世界衛生組織 (WHO) 估計全球每年約有 40 萬名兒童罹患癌症。此外，美國國家生物技術資訊中心 (NCBI) 於 2022 年 4 月進行的一項調查估計，乳癌患者貧血的發生率約為 41.1%。因此，癌症盛行率的上升正在推動市場的成長。

此外，老年人罹患癌症的可能性更大，這進一步增加了對治療各種副作用的癌症支持治療藥物的需求。例如，2022年10月，世界衛生組織（WHO）估計，到2050年，全球60歲以上的人口將增加一倍，達到21億。此外，根據美國生物技術資訊中心 (NCBI) 的數據，老年人預計會因癌症治療而出現貧血。此外，患者和醫療保健專業人員對癌症治療引起的副作用的認知不斷提高，導致人們對癌症支持治療藥物的偏好增加。

此外，隨著患者和醫療保健專業人員對癌症治療引起的副作用的認知不斷提高，人們對癌症支持治療藥物的偏好也越來越高。此外，人們越來越關注改善接受癌症治療的患者的生活品質，這推動了對有效解決方案的需求。隨著癌症發病率持續上升，尤其是兒童和老年人等特定人群，對支持性護理藥物的需求預計將持續成長，證實了它們在癌症綜合治療中的關鍵作用。

癌症支持治療藥物市場根據類型、應用、分銷管道和區域進行細分，以提供對市場的詳細評估。依類型分為紅血球生成刺激因子（ESA）、顆粒細胞增生因子（G-CSF）、止吐劑、雙磷酸鹽、鴉片類藥物、NSAID（非類固醇消炎劑）等。依用途分為乳腺癌、肺癌、結腸癌、攝護腺癌、肝癌、胃癌等。按分銷管道分類，市場分為醫院藥房、藥局和零售藥房以及線上提供者。按地區分類，我們有北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙其他歐洲國家地區）、亞太地區（中國、日本、印度、澳洲、韓國、其他亞太地區），以南美地區（巴西、沙烏地阿拉伯、非洲和其他南美地區）進行分析。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年癌症支持治療藥物市場分析的細分市場、當前趨勢、估計和動態，並確定了癌症支持治療藥物市場有前景的市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析揭示了買家和供應商的潛力，幫助相關人員做出利潤驅動的業務決策並加強供應商和買家網路。
  • 對癌症支持治療藥物市場區隔的詳細分析有助於識別市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球癌症支持治療藥物市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

使用此報告可以進行報告客製化

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 老年人口增加
      • 癌症盛行率上升，與使用抗癌藥物相關的副作用增加。
      • 更多採用癌症支持治療藥物。
    • 抑制因素
      • 標靶治療的進展
    • 機會
      • 癌症支持治療藥物研發及管線不斷增加

第4章癌症支持治療藥物市場：按類型

  • 概述
  • 紅血球生成刺激因子製劑
  • 顆粒細胞增生因子
  • 止吐藥
  • 雙磷酸鹽
  • 鴉片類藥物
  • 非類固醇消炎劑
  • 其他

第5章癌症支持治療藥物市場：依應用分類

  • 概述
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 肝癌
  • 胃癌
  • 其他

第6章癌症支持治療藥物市場：依通路分類

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 線上提供者

第7章癌症支持治療藥物市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Novartis AG
  • Johnson & Johnson
  • Amgen Inc.
  • Baxter International Inc.
  • F. Hoffmann-La Roche AG
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
Product Code: A07133
Cancer Supportive Care Drugs Market - IMG1

The main factors that drive the cancer supportive care drugs include rise in prevalence of cancer and adverse effects associated with the use of cancer drugs such as chemotherapy-induced anemia, nausea and vomiting. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated that the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market.

In addition, older people are more likely to develop cancer, which further fuels the demand for cancer support care drugs to treat various side effects. For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are expected to experience anemia as a result of cancer treatment. Furthermore, increase in awareness among patients and healthcare professionals about the side effects cause by cancer treatments has led to an increase in preference for cancer support care drugs.

Moreover, growing awareness among both patients and healthcare professionals about the side effects induced by cancer treatments has driven a preference for cancer supportive care drugs. In addition, the growth in focus on enhancing patients' quality of life during cancer therapy drives the demand for effective solutions. As cancer prevalence continues to rise, particularly among specific demographics such as children and older adults, the demand for supportive care drugs is projected to witness sustained growth, underlining their pivotal role in comprehensive cancer care.

The cancer supportive care drugs market is segmented on the basis of type, application, distribution channel, and region to provide a detailed assessment of the market. By type, it is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and others. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer and others. Depending on distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global cancer supportive care drugs market are Novartis AG, Johnson & Johnson, Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Heron Therapeutics, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Pfizer Inc. The key players have adopted strategies such as agreement and product approval to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer supportive care drugs market analysis from 2022 to 2032 to identify the prevailing cancer supportive care drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cancer supportive care drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cancer supportive care drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Erythropoiesis Stimulating Agents
  • Granulocyte Colony Stimulating Factors
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • Nonsteroidal Anti Inflammatory Drugs
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Stomach Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Amgen Inc.
    • Heron Therapeutics, Inc.
    • Merck & Co., Inc.
    • Helsinn Healthcare SA
    • Pfizer Inc.
    • Baxter International Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growth in geriatric population
      • 3.4.1.2. Rise in prevalence of cancer and adverse effects associated with use of cancer drugs.
      • 3.4.1.3. Increase in adoption of cancer supportive care drugs.
    • 3.4.2. Restraints
      • 3.4.2.1. Advancements in targeted therapy for cancer
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D and number of pipeline cancer supportive care drugs

CHAPTER 4: CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Erythropoiesis Stimulating Agents
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Granulocyte Colony Stimulating Factors
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Antiemetics
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Bisphosphonates
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Opioids
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Nonsteroidal Anti Inflammatory Drugs
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Breast Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Lung Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Colorectal Cancer
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Prostate Cancer
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Liver Cancer
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Stomach Cancer
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Others
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country

CHAPTER 6: CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Johnson & Johnson
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Amgen Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Baxter International Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. F. Hoffmann-La Roche AG
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Helsinn Healthcare SA
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Key strategic moves and developments
  • 9.7. Heron Therapeutics, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Merck & Co., Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Pfizer Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. CANCER SUPPORTIVE CARE DRUGS MARKET FOR GRANULOCYTE COLONY STIMULATING FACTORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ANTIEMETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. CANCER SUPPORTIVE CARE DRUGS MARKET FOR BISPHOSPHONATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. CANCER SUPPORTIVE CARE DRUGS MARKET FOR NONSTEROIDAL ANTI INFLAMMATORY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. CANCER SUPPORTIVE CARE DRUGS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. CANCER SUPPORTIVE CARE DRUGS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. CANCER SUPPORTIVE CARE DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. CANCER SUPPORTIVE CARE DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. CANCER SUPPORTIVE CARE DRUGS MARKET FOR LIVER CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. CANCER SUPPORTIVE CARE DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. CANCER SUPPORTIVE CARE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. CANCER SUPPORTIVE CARE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. CANCER SUPPORTIVE CARE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. UK CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 80. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 83. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 93. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 94. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 96. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 97. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 98. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 99. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 100. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 101. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 102. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 103. AMGEN INC.: KEY EXECUTIVES
  • TABLE 104. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 105. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 106. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 107. AMGEN INC.: KEY STRATERGIES
  • TABLE 108. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 109. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 110. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
  • TABLE 111. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 112. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 113. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 114. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 115. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 116. HELSINN HEALTHCARE SA: KEY EXECUTIVES
  • TABLE 117. HELSINN HEALTHCARE SA: COMPANY SNAPSHOT
  • TABLE 118. HELSINN HEALTHCARE SA: PRODUCT SEGMENTS
  • TABLE 119. HELSINN HEALTHCARE SA: PRODUCT PORTFOLIO
  • TABLE 120. HELSINN HEALTHCARE SA: KEY STRATERGIES
  • TABLE 121. HERON THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 122. HERON THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 123. HERON THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 124. HERON THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 125. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 126. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 127. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 128. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 130. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 131. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 133. PFIZER INC.: KEY EXECUTIVES
  • TABLE 134. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 135. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 136. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 137. PFIZER INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CANCER SUPPORTIVE CARE DRUGS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN CANCER SUPPORTIVE CARE DRUGS MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN CANCER SUPPORTIVE CARE DRUGS MARKET (2023-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR GRANULOCYTE COLONY STIMULATING FACTORS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ANTIEMETICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR BISPHOSPHONATES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OPIOIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR NONSTEROIDAL ANTI INFLAMMATORY DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR LIVER CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 31. CANCER SUPPORTIVE CARE DRUGS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 32. U.S. CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. UK CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 51. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 54. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 55. COMPETITIVE DASHBOARD
  • FIGURE 56. COMPETITIVE HEATMAP: CANCER SUPPORTIVE CARE DRUGS MARKET
  • FIGURE 57. TOP PLAYER POSITIONING, 2022
  • FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 71. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. HERON THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 74. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 78. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 79. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 80. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 81. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 82. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)